Jim Simons Nkarta, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nkarta, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 814,872 shares of NKTX stock, worth $4.82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

814,872

Previous 657,772 23.88%

Holding current value

$4.82 Million

Previous $4.34 Million 102.93%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$5.59 - $15.71 $878,189 - $2.47 Million	157,100 Added 23.88%	814,872 $8.81 Million
Q4 2023 Feb 13, 2024	BUY	$1.31 - $6.6 $190,212 - $958,320	145,200 Added 28.33%	657,772 $4.34 Million
Q3 2023 Nov 14, 2023	BUY	$1.39 - $2.29 $262,115 - $431,829	188,572 Added 58.2%	512,572 $712,000
Q2 2023 Aug 11, 2023	BUY	$2.19 - $5.17 $176,733 - $417,219	80,700 Added 33.17%	324,000 $710,000
Q1 2023 May 12, 2023	BUY	$3.37 - $6.3 $32,352 - $60,480	9,600 Added 4.11%	243,300 $864,000

Q4 2022 Feb 13, 2023	BUY	$5.14 - $14.35 $80,698 - $225,295	15,700 Added 7.2%	233,700 $1.4 Million
Q3 2022 Nov 14, 2022	SELL	$12.27 - $18.39 $2.3 Million - $3.45 Million	-187,600 Reduced 46.25%	218,000 $2.87 Million
Q2 2022 Aug 12, 2022	BUY	$7.77 - $19.44 $1.33 Million - $3.34 Million	171,600 Added 73.33%	405,600 $5 Million
Q1 2022 May 13, 2022	BUY	$8.66 - $14.99 $832,226 - $1.44 Million	96,100 Added 69.69%	234,000 $2.66 Million
Q4 2021 Feb 11, 2022	BUY	$12.79 - $26.88 $1.37 Million - $2.88 Million	107,300 Added 350.65%	137,900 $2.12 Million
Q3 2021 Nov 12, 2021	BUY	$26.67 - $38.76 $816,102 - $1.19 Million	30,600 New	30,600 $851,000

Others Institutions Holding NKTX

# of Institutions

121

Shares Held

52.8M

Call Options Held

145K

Put Options Held

114K

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $288M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account